LO-015 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks

Richard Furie, Eric F. Morand, Kenneth B Kalunian et al.|Unknown|2023

Cited by 0